^
Association details:
Biomarker:No biomarker
Cancer:Leiomyosarcoma
Drug:Yondelis (trabectedin) (Alkylating agent, DNA inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
YONDELIS is an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Trabectedin is included for palliative therapy as a category 1 recommendation for LPS and LMS (L-type) and as category 2A for non-L-type sarcomas...